David C. Hastings - 04 Feb 2025 Form 4 Insider Report for Arbutus Biopharma Corp (ABUS)

Signature
/s/ David C. Hastings
Issuer symbol
ABUS
Transactions as of
04 Feb 2025
Transactions value $
-$72,827
Form type
4
Filing time
05 Feb 2025, 16:02:55
Previous filing
21 Jun 2024
Next filing
19 Feb 2025

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABUS Common Shares Sale -$72.8K -22.2K -12.19% $3.28 160K 04 Feb 2025 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Represents the non-discretionary sale of common shares pursuant to the Reporting Person's 10b5-1 Plan, adopted on March 6, 2023, to satisfy the Reporting Person's tax obligations with respect to the vesting of previous grants of restricted stock units.